TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast

Masayuki Yoshida, Reiko Ogawa, Hiroshi Yoshida, Akiko Maeshima, Yae Kanai, Takayuki Kinoshita, Nobuyoshi Hiraoka, Shigeki Sekine

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background:Phyllodes tumors are rare fibroepithelial neoplasms of the breast, which carry the potential risk of local recurrence and metastasis. Phyllodes tumors share several histological features with fibroadenomas, and no widely accepted markers for distinguishing these lesions have been identified.Methods:We analyzed molecular abnormalities related to telomere elongation in tumors, including TERT promoter mutations, as well as loss of expression of ATRX and DAXX, in a total of 104 phyllodes tumors and fibroadenomas.Results:Sequencing analyses showed that TERT promoter mutations were frequent in phyllodes tumors (30/46, 65%), but rare in fibroadenomas (4/58, 7%). Among phyllodes tumors, the mutations were more frequent in borderline tumors (13/15, 87%), but were also common in benign (9/18, 50%) and malignant tumors (8/13, 62%). Remarkably, all but one TERT promoter-mutated tumor also contained MED12 mutations, indicating that these mutations are strongly associated (P=8.4 × 10 -6). Expression of ATRX and DAXX, as evaluated by immunohistochemistry, was retained in all tumors.Conclusions:Our observations suggest a critical role of TERT promoter mutations, in cooperation with MED12 mutations, in the development of phyllodes tumors. Because TERT promoter mutations are rare among fibroadenomas, their detection may be of potential use in discriminating between phyllodes tumors and fibroadenomas.

Original languageEnglish
Pages (from-to)1244-1248
Number of pages5
JournalBritish Journal of Cancer
Volume113
Issue number8
DOIs
Publication statusPublished - 2015 Oct 20
Externally publishedYes

Fingerprint

Phyllodes Tumor
Fibroadenoma
Breast
Mutation
Fibroepithelial Neoplasms
Neoplasms
Telomere
Carcinogens
Immunohistochemistry
Neoplasm Metastasis
Recurrence

Keywords

  • breast
  • fibroadenoma
  • MED12
  • phyllodes tumor
  • TERT

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast. / Yoshida, Masayuki; Ogawa, Reiko; Yoshida, Hiroshi; Maeshima, Akiko; Kanai, Yae; Kinoshita, Takayuki; Hiraoka, Nobuyoshi; Sekine, Shigeki.

In: British Journal of Cancer, Vol. 113, No. 8, 20.10.2015, p. 1244-1248.

Research output: Contribution to journalArticle

Yoshida, M, Ogawa, R, Yoshida, H, Maeshima, A, Kanai, Y, Kinoshita, T, Hiraoka, N & Sekine, S 2015, 'TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast', British Journal of Cancer, vol. 113, no. 8, pp. 1244-1248. https://doi.org/10.1038/bjc.2015.326
Yoshida, Masayuki ; Ogawa, Reiko ; Yoshida, Hiroshi ; Maeshima, Akiko ; Kanai, Yae ; Kinoshita, Takayuki ; Hiraoka, Nobuyoshi ; Sekine, Shigeki. / TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast. In: British Journal of Cancer. 2015 ; Vol. 113, No. 8. pp. 1244-1248.
@article{b15ed7a6d26449e3b9b0aa78376505ae,
title = "TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast",
abstract = "Background:Phyllodes tumors are rare fibroepithelial neoplasms of the breast, which carry the potential risk of local recurrence and metastasis. Phyllodes tumors share several histological features with fibroadenomas, and no widely accepted markers for distinguishing these lesions have been identified.Methods:We analyzed molecular abnormalities related to telomere elongation in tumors, including TERT promoter mutations, as well as loss of expression of ATRX and DAXX, in a total of 104 phyllodes tumors and fibroadenomas.Results:Sequencing analyses showed that TERT promoter mutations were frequent in phyllodes tumors (30/46, 65{\%}), but rare in fibroadenomas (4/58, 7{\%}). Among phyllodes tumors, the mutations were more frequent in borderline tumors (13/15, 87{\%}), but were also common in benign (9/18, 50{\%}) and malignant tumors (8/13, 62{\%}). Remarkably, all but one TERT promoter-mutated tumor also contained MED12 mutations, indicating that these mutations are strongly associated (P=8.4 × 10 -6). Expression of ATRX and DAXX, as evaluated by immunohistochemistry, was retained in all tumors.Conclusions:Our observations suggest a critical role of TERT promoter mutations, in cooperation with MED12 mutations, in the development of phyllodes tumors. Because TERT promoter mutations are rare among fibroadenomas, their detection may be of potential use in discriminating between phyllodes tumors and fibroadenomas.",
keywords = "breast, fibroadenoma, MED12, phyllodes tumor, TERT",
author = "Masayuki Yoshida and Reiko Ogawa and Hiroshi Yoshida and Akiko Maeshima and Yae Kanai and Takayuki Kinoshita and Nobuyoshi Hiraoka and Shigeki Sekine",
year = "2015",
month = "10",
day = "20",
doi = "10.1038/bjc.2015.326",
language = "English",
volume = "113",
pages = "1244--1248",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast

AU - Yoshida, Masayuki

AU - Ogawa, Reiko

AU - Yoshida, Hiroshi

AU - Maeshima, Akiko

AU - Kanai, Yae

AU - Kinoshita, Takayuki

AU - Hiraoka, Nobuyoshi

AU - Sekine, Shigeki

PY - 2015/10/20

Y1 - 2015/10/20

N2 - Background:Phyllodes tumors are rare fibroepithelial neoplasms of the breast, which carry the potential risk of local recurrence and metastasis. Phyllodes tumors share several histological features with fibroadenomas, and no widely accepted markers for distinguishing these lesions have been identified.Methods:We analyzed molecular abnormalities related to telomere elongation in tumors, including TERT promoter mutations, as well as loss of expression of ATRX and DAXX, in a total of 104 phyllodes tumors and fibroadenomas.Results:Sequencing analyses showed that TERT promoter mutations were frequent in phyllodes tumors (30/46, 65%), but rare in fibroadenomas (4/58, 7%). Among phyllodes tumors, the mutations were more frequent in borderline tumors (13/15, 87%), but were also common in benign (9/18, 50%) and malignant tumors (8/13, 62%). Remarkably, all but one TERT promoter-mutated tumor also contained MED12 mutations, indicating that these mutations are strongly associated (P=8.4 × 10 -6). Expression of ATRX and DAXX, as evaluated by immunohistochemistry, was retained in all tumors.Conclusions:Our observations suggest a critical role of TERT promoter mutations, in cooperation with MED12 mutations, in the development of phyllodes tumors. Because TERT promoter mutations are rare among fibroadenomas, their detection may be of potential use in discriminating between phyllodes tumors and fibroadenomas.

AB - Background:Phyllodes tumors are rare fibroepithelial neoplasms of the breast, which carry the potential risk of local recurrence and metastasis. Phyllodes tumors share several histological features with fibroadenomas, and no widely accepted markers for distinguishing these lesions have been identified.Methods:We analyzed molecular abnormalities related to telomere elongation in tumors, including TERT promoter mutations, as well as loss of expression of ATRX and DAXX, in a total of 104 phyllodes tumors and fibroadenomas.Results:Sequencing analyses showed that TERT promoter mutations were frequent in phyllodes tumors (30/46, 65%), but rare in fibroadenomas (4/58, 7%). Among phyllodes tumors, the mutations were more frequent in borderline tumors (13/15, 87%), but were also common in benign (9/18, 50%) and malignant tumors (8/13, 62%). Remarkably, all but one TERT promoter-mutated tumor also contained MED12 mutations, indicating that these mutations are strongly associated (P=8.4 × 10 -6). Expression of ATRX and DAXX, as evaluated by immunohistochemistry, was retained in all tumors.Conclusions:Our observations suggest a critical role of TERT promoter mutations, in cooperation with MED12 mutations, in the development of phyllodes tumors. Because TERT promoter mutations are rare among fibroadenomas, their detection may be of potential use in discriminating between phyllodes tumors and fibroadenomas.

KW - breast

KW - fibroadenoma

KW - MED12

KW - phyllodes tumor

KW - TERT

UR - http://www.scopus.com/inward/record.url?scp=84945494051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945494051&partnerID=8YFLogxK

U2 - 10.1038/bjc.2015.326

DO - 10.1038/bjc.2015.326

M3 - Article

VL - 113

SP - 1244

EP - 1248

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -